论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Sun F, Peng HX, Gao QF, Li SQ, Zhang J, Chen QG, Jiang YH, Zhang L, Wang XZ, Ying HQ
Received 6 March 2018
Accepted for publication 24 April 2018
Published 19 July 2018 Volume 2018:10 Pages 2151—2161
DOI https://doi.org/10.2147/CMAR.S167398
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Dr Leylah Drusbosky
Introduction: Inflammation and nutrition are considered as two important causes
leading to the progression and poor survival of colorectal cancer (CRC). The
objective of this study is to investigate the prognostic significance of
preoperative albumin-to-fibrinogen ratio (AFR), fibrinogen-to-pre-albumin ratio
(FPR), fibrinogen (Fib), albumin (Alb), and pre-albumin (pre-Alb) in CRC
individuals.
Materials and
methods: In this study, 3 years’ follow-up
was carried out in 702 stage I–III resected CRC patients diagnosed between
January 2008 and December 2013. The optimal cutoff points and prognostic values
of AFR, FPR, Fib, Alb, pre-Alb, and a novel carcinoembryonic antigen
(CEA)-carbohydrate antigen 19-9 (CA199)-FPR (CCF) score were assessed by X-tile
software, Kaplan–Meier curve, and Cox regression model. We established the CRC
prognostic nomogram, and its predictive efficacy was determined by Harrell’s
concordance index (c-index).
Results: Our results showed that high FPR was obviously correlated with
poor survival of CRC patients. The prognostic predictive efficacy of CCF score
was superior to FPR, CEA, CA199, CEA-CA199 (CCI), and CEA-FPR (CFI) score.
Moreover, stage II–III patients harboring high FPR or elevated CCF (score≥1)
could benefit from adjuvant chemotherapy, rather than those with low FPR or CCF
(score=0). Additionally, the c-index (0.728) of the nomogram containing CCF
score was significantly higher than that (0.626) without it (p <0.01).
Conclusion: These findings illustrated that FPR and CCF score were promising
biomarkers to predict the prognosis of CRC and to classify the stage II–III
patients who could benefit from the adjuvant chemotherapy.
Keywords: inflammation, colorectal cancer, FPR, CCF score, survival